Atef, L., Mansour, S., Ibrahim, R., Atwa, M. (2022). Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity. Suez Canal University Medical Journal, 25(2), 40-47. doi: 10.21608/scumj.2022.249731
Lina Atef; Sahar F. Mansour; Rasha M. Ibrahim; Mona A. Atwa. "Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity". Suez Canal University Medical Journal, 25, 2, 2022, 40-47. doi: 10.21608/scumj.2022.249731
Atef, L., Mansour, S., Ibrahim, R., Atwa, M. (2022). 'Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity', Suez Canal University Medical Journal, 25(2), pp. 40-47. doi: 10.21608/scumj.2022.249731
Atef, L., Mansour, S., Ibrahim, R., Atwa, M. Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity. Suez Canal University Medical Journal, 2022; 25(2): 40-47. doi: 10.21608/scumj.2022.249731
Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity
1Department of Dermatology and Venereology, Faculty of Medicine, Suez Canal University
2Department of Pathology, Faculty of Medicine, Suez Canal University.
Abstract
Background: Vitiligo is a pigmentary disorder defined by the presence of well-circumscribed milky-white macules on the skin and mucous membranes caused by the loss of functional melanocytes in the affected areas. There are various theories for vitiligo's origin, including neurological, auto cytotoxic, genetic, and immunological theories. Because the cytokine IL-36 is involved in the development and pathophysiology of autoimmune disorders such as psoriasis, rheumatoid arthritis, and SLE, it’s probable that IL-36 plays a role in the progression of vitiligo. Objectives: The purpose of this study was to look at the tissue expression of IL-36 in vitiligo lesions and non-lesional skin. Patients and Methods: There were 41 vitiligo patients and 5 healthy controls in this cross-sectional analytic study. Each patient's history was collected, and all patients were examined by a dermatologist to determine the pattern, activity, and severity of vitiligo. Biopsies were extracted from lesional and nonlesional skin of all patients, and immunohistochemistry staining for IL-36 expression was performed. Results: In vitiligo patients, IL-36 expression was elevated in both lesional and nonlesional skin, primarily in the inflammatory infiltrate in the dermis. In terms of age of onset, sex, disease duration, course, activity severity, and pattern, there is no significant variation in IL-36 expression. Conclusion: Our findings suggested that IL 36 may have a role in the etiology of vitiligo, which could shed light on the disease's pathogenesis.
View on SCiNiTO
Top